Apparatus for optimizing a patient's insulin dosage regimen
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12183445-B2
Publication Date
2024-12-31
Expiration Date
Abstract
An apparatus for optimizing a patient's insulin dosage regimen over time, comprising: at least a first computer-readable memory for storing data inputs corresponding at least to one or more components in a patient's present insulin dosage regimen and the patient's blood-glucose-level measurements determined at a plurality of times; a processor operatively connected to the at least first computer-readable memory, the processor programmed at least to determine from the data inputs corresponding to the patient's blood-glucose-level measurements determined at a plurality of times whether and by how much to vary at least one of the one or more components of the patient's present insulin dosage regimen in order to maintain the patient's future blood-glucose-level measurements within a predefined range; and a display operative to display information corresponding to at least the patient's present insulin dosage regimen.
Core Innovation
The invention relates to an apparatus for optimizing an insulin dosage regimen of a patient over time. The apparatus includes at least a first computer-readable memory for storing programming instructions, a plurality of data inputs corresponding to one or more components in the insulin dosage regimen, a plurality of blood-glucose-level measurements determined at a plurality of times over a predefined period of time, and a timer for counting to a periodic update evaluation over the predefined period of time.
The processor executes the stored programming instructions to determine, at the end of the predefined period of time, from the blood-glucose-level measurements whether and by how much to adjust at least one component of the insulin dosage regimen to maintain future blood-glucose-level measurements within a predefined range. The processor also determines whether an excessive number of hypoglycemic events has occurred over the predefined period of time.
Upon determining that an excessive number of hypoglycemic events has occurred, the apparatus reduces at least one component of the insulin dosage regimen and prevents an increase in an insulin dosage of the patient at the next periodic update evaluation. The invention also includes constraints on long-acting insulin dosage such that any two successive such adjusted dosages do not both fall below and above the dosage which they immediately succeed, and it treats the insulin dosage regimen as adjusted even if no adjustment is made at a periodic evaluation.
Whenever the insulin dosage regimen is adjusted, whether in consequence of a periodic update evaluation or an asynchronous update, the timer counting to the next periodic update evaluation is reset.
Claims Coverage
The independent claim includes 6 inventive features. It defines an apparatus-level framework with periodic evaluation, hypoglycemia-driven dose component reduction, long-acting insulin adjustment constraints, and timer reset behavior.
Periodic evaluation over a predefined period
Determining, at the end of the predefined period of time, from a plurality of blood-glucose-level measurements determined at a plurality of times whether and by how much to adjust at least one component of the insulin dosage regimen to maintain future blood-glucose-level measurements within a predefined range.
Hypoglycemic-event detection and component reduction
Determining whether an excessive number of hypoglycemic events has occurred over the predefined period of time, and reducing, upon a determination that an excessive number of hypoglycemic events has occurred, at least one of the one or more components of the insulin dosage regimen.
Preventing increases at the next periodic update after reduction
Preventing, upon a reduction in at least one of the one or more components of the insulin dosage regimen of the patient, an increase in an insulin dosage of the patient at a next periodic update evaluation.
Long-acting insulin adjustment constraint across successive adjusted dosages
Wherein a long-acting insulin dosage of the patient may not be adjustable so that any two successive such adjusted dosages fall below and above the dosage which they immediately succeed.
Treating the regimen as adjusted even when no adjustment is made
Wherein when a periodic evaluation of the patient insulin dosage regimen is undertaken, the insulin dosage regimen is treated as having been adjusted even if there has been no adjustment made to the insulin dosage regimen.
Timer reset upon any adjustment including asynchronous updates
Wherein any time the insulin dosage regimen is adjusted, whether in consequence of a periodic update evaluation or an asynchronous update, the timer counting to the next periodic update evaluation is reset.
Across the independent claim, the apparatus stores insulin-regimen components and time-distributed blood-glucose measurements, performs periodic update evaluations over a predefined period, adjusts regimen components to maintain future measurements within a predefined range, reduces regimen components when an excessive number of hypoglycemic events is detected, prevents increases at the next periodic update after such reduction, enforces a constraint on long-acting insulin adjustment, treats periodic evaluations as regimen adjustments even when no adjustment is made, and resets the periodic timer whenever any adjustment occurs, including asynchronous updates.
Stated Advantages
Maintain future blood-glucose-level measurements of the patient within a predefined range.
Reduce insulin-dosage regimen components when an excessive number of hypoglycemic events has occurred over the predefined period of time.
Prevent an increase in insulin dosage at the next periodic update evaluation after reducing at least one component due to excessive hypoglycemic events.
Constrain long-acting insulin dosage adjustment to avoid specified successive below/above switching behavior relative to the dosage immediately succeeded.
Documented Applications
No documented applications found
Interested in licensing this patent?